Synthesis and in vitro anticancer activity of some 2-oxindoline derivatives as potential CDK2 inhibitors

References

• Abdel-Aziz, H. A., Elsaman, T., Al-Dhfyan, A., Attia, M. I., Al-Rashood, K. A., & Al-Obaid, A. R. (2013). Synthesis and anticancer potential of certain novel 2-oxo-N'-(2-oxoindolin-3-ylidene)-2H-chromene-3-carbohydrazides. European Journal of Medicinal Chemistry, 70, 358–363. https://doi.org/10.1016/j.ejmech.2013.09.060
   PubMed Web of Science ®Google Scholar
• Al-Sanea, M. M., Obaidullah, A. J., Shaker, M. E., Chilingaryan, G., Alanazi, M. M., Alsaif, N. A., Alkahtani, H. M., Alsubaie, S. A., & Abdelgawad, M. A. (2021). A new CDK2 inhibitor with 3-hydrazonoindolin-2-one scaffold endowed with anti-breast cancer activity: Design, synthesis, biological evaluation, and in silico insights. Molecules (Basel, Switzerland), 26(2), 412. https://doi.org/10.3390/molecules2602041
   PubMed Web of Science ®Google Scholar
• Al-Warhi, T., Abo-Ashour, M. F., Almahli, H., Alotaibi, O. J., Al-Sanea, M. M., Al-Ansary, G. H., Ahmed, H. Y., Elaasser, M. M., Eldehna, W. M., & Abdel-Aziz, H. A. (2020a). Novel [(N-alkyl-3-indolylmethylene)hydrazono]oxindoles arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and Bcl-2: Synthesis, biological evaluation and in silico studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), 1300–1309. https://doi.org/10.1080/14756366.2020.1773814
   PubMed Web of Science ®Google Scholar
• Al-Warhi, T., El Kerdawy, A. M., Aljaeed, N., Ismael, O. E., Ayyad, R. R., Eldehna, W. M., Abdel-Aziz, H. A., & Al-Ansary, G. H. (2020b). Synthesis, biological evaluation and in silico studies of certain oxindole-indole conjugates as anticancer CDK inhibitors. Molecules (Basel, Switzerland), 25(9), 2031. https://doi.org/10.3390/molecules25092031
   PubMed Web of Science ®Google Scholar
• Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015). The history and future of targeting cyclin-dependent kinases in cancer therapy. Nature Reviews. Drug Discovery, 14(2), 130–146. https://doi.org/10.1038/nrd4504
   PubMed Web of Science ®Google Scholar
• Bayoumy, B. E., El Bahaie, S., & Abdel-Rahman, A. E. (1984). Studies on spiroheterocyclic nitrogen compounds. Part 1 : Synthesis of some new spiro pyrazolines, isoxazolines and pyrimidinethiones containing benzanilide moiety. Journal of Indian Chemical Society, 61, 520–522. https://doi.org/10.5281/zenodo.6327114
   Web of Science ®Google Scholar
• Berkowitz, D. B. (1990). A new method for the α-vinylation of protected α-amino acids; ethylene oxide as vinyl cation equivalent. Synthetic Communications, 20(12), 1819–1829. https://doi.org/10.1080/00397919008053106
   Web of Science ®Google Scholar
• Campos, M. C., Castro-Pinto, D. B., Ribeiro, G. A., Berredo-Pinho, M. M., Gomes, L. H., da Silva Bellieny, M. S., Goulart, C. M., Echevarria, A., & Leon, L. L. (2013). P-glycoprotein efflux pump plays an important role in Trypanosoma cruzi drug resistance. Parasitology Research, 112(6), 2341–2351. https://doi.org/10.1007/s00436-013-3398-z
   PubMed Web of Science ®Google Scholar
• Cancer, WHO. (2020). https://www.paho.org/en/topics/cancer
   Google Scholar
• CDK2 Assay Kit. https://bpsbioscience.com/media/wysiwyg/Kinases/79599_2
   Google Scholar
• Chung, J. H., & Bunz, F. (2010). Cdk2 is required for p53-independent G2/M checkpoint control. PLoS Genetics, 6(2), e1000863. https://doi.org/10.1371/journal.pgen.1000863
   PubMed Web of Science ®Google Scholar
• Czeleń, P., Skotnicka, A., & Szefler, B. (2022). Designing and synthesis of new isatin derivatives as potential CDK2 inhibitors. International Journal of Molecular Sciences, 23(14), 8046. https://doi.org/10.3390/ijms23148046
   PubMed Web of Science ®Google Scholar
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• Davies, T. G., Tunnah, P., Meijer, L., Marko, D., Eisenbrand, G., Endicott, J. A., & Noble, M. E. (2001). Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure (London, England : 1993), 9(5), 389–397. https://doi.org/10.1016/S0969-2126(01)00598-6
   PubMed Web of Science ®Google Scholar
• De Boer, L., Oakes, V., Beamish, H., Giles, N., Stevens, F., Somodevilla-Torres, M., Desouza, C., & Gabrielli, B. (2008). Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events. Oncogene, 27(31), 4261–4268. https://doi.org/10.1038/onc.2008.74
   PubMed Web of Science ®Google Scholar
• Decalf, V. H., Huion, A. M. J., Benoit, D. F., Denys, M. A., Petrovic, M., & Everaert, K. C. M. M. (2017). Older people’s preferences for side effects associated with antimuscarinic treatments of overactive bladder: A discrete-choice experiment. Drugs & Aging, 34(8), 615–623. https://doi.org/10.1007/s40266-017-0474-6
   PubMed Web of Science ®Google Scholar
• Demir, A. S., Sesenoglu, Ö., Ülkü, D., & Arici, C. (2003). Novel enantioselective synthesis of both enantiomers of furan-2-yl amines and amino acids. Helvetica Chimica Acta, 86(1), 91–105. https://doi.org/10.1002/hlca.200390022
   Web of Science ®Google Scholar
• Dhokne, P., Sakla, A. P., & Shankaraiah, N. (2021). Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances. European Journal of Medicinal Chemistry, 216, 113334. https://doi.org/10.1016/j.ejmech.2021.113334
   PubMed Web of Science ®Google Scholar
• Donjerkovic, D., & Scott, D. W. (2000). Regulation of the G1 phase of the mammalian cell cycle. Cell Research, 10(1), 1–16. https://doi.org/10.1038/sj.cr.7290031
   PubMed Web of Science ®Google Scholar
• Dweedar, H. E., Mahrous, H., Ibrahim, H. S., & Abdel-Aziz, H. A. (2014). Analogue-based design, synthesis and biological evaluation of 3-substituted-(methylenehydrazono)indolin-2-ones as anticancer agents. European Journal of Medicinal Chemistry, 78, 275–280. https://doi.org/10.1016/j.ejmech.2014.03.058
   PubMed Web of Science ®Google Scholar
• Egan, W. J., Merz, K. M., Jr., & Baldwin, J. J. (2000). Prediction of drug absorption using multivariate statistics. Journal of Medicinal Chemistry, 43(21), 3867–3877. https://doi.org/10.1021/jm000292e48
   PubMed Web of Science ®Google Scholar
• Eldehna, W. M., Al-Rashood, S. T., Al-Warhi, T., Eskandrani, R. O., Alharbi, A., & El Kerdawy, A. M. (2021). Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: Design, synthesis, biological evaluation, and in silico studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 36(1), 270–285. https://doi.org/10.1080/14756366.2020.186210124
   PubMed Web of Science ®Google Scholar
• Eldehna, W. M., El Hassab, M. A., Abo-Ashour, M. F., Al-Warhi, T., Elaasser, M. M., Safwat, N. A., Suliman, H., Ahmed, M. F., Al-Rashood, S. T., Abdel-Aziz, H. A., & El-Haggar, R. (2021). Development of isatin-thiazolo[3,2-a]benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological and molecular dynamics investigations. Bioorganic Chemistry, 110, 104748. https://doi.org/10.1016/j.bioorg.2021.104748
   PubMed Web of Science ®Google Scholar
• El-Miligy, M. M., Rida, S. M., Ashour, F. A., Badr, M. H., El-Bassiony, E. M., El-Demellawy, M. A., & Omar, A. M. (2018). Dual inhibitors of hepatitis C virus and hepatocellular carcinoma: Design, synthesis and docking studies. Future Science OA, 4(1), FSO252. https://doi.org/10.4155/fsoa-2017-0075
   PubMed Web of Science ®Google Scholar
• Feng, C.-T., Wang, L.-D., Yan, Y.-G., Liu, J., & Li, S. (2012). Synthesis and antitumor evaluation of some 1,3,4-oxadiazole-2(3H)-thione and 1,2,4-triazole-5(1H)-thione derivatives. Medicinal Chemistry Research, 21(3), 315–320. https://doi.org/10.1007/s00044-010-9544-6
   Web of Science ®Google Scholar
• Ghose, A. K., Viswanadhan, V. N., & Wendoloski, J. J. (1999). A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. Journal of Combinatorial Chemistry, 1(1), 55–68. https://doi.org/10.1021/cc9800071
   PubMedGoogle Scholar
• Gil-Gómez, G. (2004). Measurement of changes in apoptosis and cell cycle regulatory kinase Cdk2. Methods in Molecular Biology (Clifton, N.J.), 282, 131–144. https://doi.org/10.1385/1-59259-812-9:131
   PubMedGoogle Scholar
• Guardavaccaro, D., & Pagano, M. (2006). Stabilizers and destabilizers controlling cell cycle oscillators. Molecular Cell, 22(1), 1–4. https://doi.org/10.1016/j.molcel.2006.03.017
   PubMed Web of Science ®Google Scholar
• Hu, B., Mitra, J., van den Heuvel, S., & Enders, G. H. (2001). S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Molecular and Cellular Biology, 21(8), 2755–2766. https://doi.org/10.1128/MCB.21.8.2755-2766.2001
   PubMed Web of Science ®Google Scholar
• Iyer, V. V. (2015). Small molecules for immunomodulation in cancer: A review. Anti-Cancer Agents in Medicinal Chemistry, 15(4), 433–452. https://doi.org/10.2174/1871520615666141210152128
   PubMed Web of Science ®Google Scholar
• Jautelat, R., Brumby, T., Schäfer, M., Briem, H., Eisenbrand, G., Schwahn, S., Krüger, M., Lücking, U., Prien, O., & Siemeister, G. (2005). From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors. Chembiochem, 6(3), 531–540. https://doi.org/10.1002/cbic.200400108
   PubMed Web of Science ®Google Scholar
• Kang, S., La, M. T., & Kim, H.-K. (2018). Convenient metal-free direct oxidative amidation of aldehyde using dibromoisocyanuric acid under mild conditions. Tetrahedron Letters, 59(39), 3541–3546. https://doi.org/10.1016/j.tetlet.2018.08.026
   Web of Science ®Google Scholar
• Kargbo, R. B. (2022). Selective cyclin-dependent kinase inhibitors and their application in cancer therapy. ACS Medicinal Chemistry Letters, 13(10), 1561–1563. https://doi.org/10.1021/acsmedchemlett.2c00417
   PubMedGoogle Scholar
• Korashy, H. M., Maayah, Z. H., Al Anazi, F. E., Alsaad, A. M., Alanazi, I. O., Belali, O. M., Al-Atawi, F. O., & Alshamsan, A. (2017). Sunitinib inhibits breast cancer cell proliferation by inducing apoptosis, cell-cycle arrest and DNA repair while inhibiting NF-κB signaling pathways. Anticancer Research, 37(9), 4899–4909. https://doi.org/10.21873/anticanres.11899
   PubMed Web of Science ®Google Scholar
• Lane, M. E., Yu, B., Rice, A., Lipson, K. E., Liang, C., Sun, L., Tang, C., McMahon, G., Pestell, R. G., & Wadler, S. (2001). A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Research, 61(16), 6170–6177. https://aacrjournals.org/cancerres/article/61/16/6170/507818
   PubMed Web of Science ®Google Scholar
• Laphanuwat, P., & Jirawatnotai, S. (2019). Immunomodulatory roles of cell cycle regulators. Frontiers in Cell and Developmental Biology, 7, 23. https://doi.org/10.3389/fcell.2019.00023
   PubMed Web of Science ®Google Scholar
• Lin, H. S., Huang, Y. L., Wang, Y. S., Hsiao, E., Hsu, T. A., Shiao, H. Y., Jiaang, W. T., Sampurna, B. P., Lin, K. H., Wu, M. S., Lai, G. M., & Yuh, C. H. (2019). Identification of novel anti-liver cancer small molecules with better therapeutic index than Sorafenib via Zebrafish Drug screening platform. Cancers, 11(6), 739. https://doi.org/10.3390/cancers11060739
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1–3), 3–26. https://doi.org/10.1016/s0169-409x(00)00129-0
   PubMed Web of Science ®Google Scholar
• Lynch, T., & Price, A. (2007). The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. American Family Physician, 76(3), 391–396. https://www.aafp.org/pubs/afp/issues/2007/0801/p391.html
   PubMed Web of Science ®Google Scholar
• Martin, M. P., Endicott, J. A., & Noble, M. E. M. (2017). Structure-based discovery of cyclin-dependent protein kinase inhibitors. Essays in Biochemistry, 61(5), 439–452. https://doi.org/10.1042/EBC20170040
   PubMed Web of Science ®Google Scholar
• Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65(1-2), 55–63. https://doi.org/10.1016/0022-1759(83)90303-4
   PubMed Web of Science ®Google Scholar
• Muegge, I., Heald, S. L., & Brittelli, D. (2001). Simple selection criteria for drug-like chemical matter. Journal of Medicinal Chemistry, 44(12), 1841–1846. https://doi.org/10.1021/jm015507e
   PubMed Web of Science ®Google Scholar
• Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., & Riccardi, C. (1991). A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. Journal of Immunological Methods, 139(2), 271–279. https://doi.org/10.1016/0022-1759(91)90198-o
   PubMed Web of Science ®Google Scholar
• Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. C. (2015). Targeting cyclin-dependent kinases in human cancers: From small molecules to Peptide inhibitors. Cancers, 7(1), 179–237. https://doi.org/10.3390/cancers7010179
   PubMed Web of Science ®Google Scholar
• Pozarowski, P., & Darzynkiewicz, Z. (2004). Analysis of cell cycle by flow cytometry. Methods in Molecular Biology (Clifton, N.J.), 281, 301–311. https://doi.org/10.1385/1-59259-811-0:301
   PubMedGoogle Scholar
• Rottenberg, M. (1975). Hydrazide as acarboxyl protecting group deprotection by acidolysis. Helvetica Chimica Acta, 58, 521–523. https://doi.org/10.1002/hlca.19750580222
   Web of Science ®Google Scholar
• Sabt, A., Eldehna, W. M., Al-Warhi, T., Alotaibi, O. J., Elaasser, M. M., Suliman, H., & Abdel-Aziz, H. A. (2020). Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: Synthesis, biological evaluation and in silico insights. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), 1616–1630. https://doi.org/10.1080/14756366.2020.180625957
   PubMed Web of Science ®Google Scholar
• Said, M. A., Abdelrahman, M. A., Abourehab, M. A. S., Fares, M., & Eldehna, W. M. (2022). A patent review of anticancer CDK2 inhibitors (2017-present). Expert Opinion on Therapeutic Patents, 32(8), 885–898. https://doi.org/10.1080/13543776.2022.2078193
   PubMed Web of Science ®Google Scholar
• Sander, T., Freyss, J., von Korff, M., Reich, J. R., & Rufener, C. (2009). OSIRIS, an entirely in-house developed drug discovery informatics system. Journal of Chemical Information and Modeling, 49(2), 232–246. https://doi.org/10.1021/ci800305f53
   PubMed Web of Science ®Google Scholar
• Sander, T. (2001). Actelion’s property explorer. https://www.organic-chemistry.org/prog/peo/
   Google Scholar
• Shafei, A., El-Bakly, W., Sobhy, A., Wagdy, O., Reda, A., Aboelenin, O., Marzouk, A., El Habak, K., Mostafa, R., Ali, M. A., & Ellithy, M. (2017). A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 95, 1209–1218. https://doi.org/10.1016/j.biopha.2017.09.059
   PubMed Web of Science ®Google Scholar
• Tolosa, L., Donato, M. T., & Gómez-Lechón, M. J. (2015). General cytotoxicity assessment by means of the MTT assay. Methods in Molecular Biology (Clifton, N.J.), 1250, 333–348. https://doi.org/10.1007/978-1-4939-2074-7_26
   PubMedGoogle Scholar
• Tugrak, M., Gul, H. I., Demir, Y., Levent, S., & Gulcin, I. (2021). Synthesis and in vitro carbonic anhydrases and acetylcholinesterase inhibitory activities of novel imidazolinone-based benzenesulfonamides. Archiv der Pharmazie, 354(4), e2000375. https://doi.org/10.1002/ardp.202000375
   PubMed Web of Science ®Google Scholar
• Veber, D. F., Johnson, S. R., Cheng, H. Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry, 45(12), 2615–2623. https://doi.org/10.1021/jm020017n
   PubMed Web of Science ®Google Scholar
• Vermes, I., Haanen, C., Steffens-Nakken, H., & Reutelingsperger, C. (1995). A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. Journal of Immunological Methods, 184(1), 39–51. https://doi.org/10.1016/0022-1759(95)00072-i
   PubMed Web of Science ®Google Scholar
• Wu, Q., Yang, Z., Nie, Y., Shi, Y., & Fan, D. (2014). Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Letters, 347(2), 159–166. https://doi.org/10.1016/j.canlet.2014.03.013
   PubMed Web of Science ®Google Scholar
• Yadlapalli, R. K., Chourasia, O. P., Jogi, M. P., Podile, A. R., & Perali, R. S. (2013). Design, synthesis and in vitro antimicrobial activity of novel phenylbenzamido-aminothiazole-based azasterol mimics. Medicinal Chemistry Research, 22(6), 2975–2983. https://doi.org/10.1007/s00044-012-0314-5
   Web of Science ®Google Scholar
• Zhong, Z., Yu, J., Virshup, D. M., & Madan, B. (2020). Wnts and the hallmarks of cancer. Cancer and Metastasis Reviews, 39(3), 625–645. https://doi.org/10.1007/s10555-020-09887-6
   PubMed Web of Science ®Google Scholar